Galderma Group stock
Price history
+31.42% over the period1 year: from CHF 146.40 (November 17, 2025) to CHF 192.40 (November 16, 2026), +31.42%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | CHF 192.40 |
| October 30, 2026 | CHF 192.85 |
| September 30, 2026 | CHF 165.85 |
| August 31, 2026 | CHF 167.90 |
| July 31, 2026 | CHF 175.75 |
| June 30, 2026 | CHF 183.90 |
| May 29, 2026 | CHF 166.55 |
| April 30, 2026 | CHF 163.80 |
| March 31, 2026 | CHF 153.40 |
| February 27, 2026 | CHF 145.90 |
| January 30, 2026 | CHF 143.90 |
| December 30, 2025 | CHF 162.10 |
| November 28, 2025 | CHF 160.00 |
| November 17, 2025 | CHF 146.40 |
At a glance
The company
Develops and markets dermatology products including injectable aesthetics, skincare and therapeutic treatments worldwide
Latest results
Quarter to September 30, 2026
Next event
TickerLandia's take on Galderma Group
- Pricier than similar companies: trailing 12-month P/E 66 vs 25 (+164%) in a group of 11.
- Strong point: Growth (78/100 in its group). Weak point: Dividend (12/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−2.34% from the 52-week high
Analysts · 17 analysts
Average targetCHF 210.76+9.54% vs. price
Buy 14 · Hold 2 · Sell 1 · Buy
TickerLandia Fingerprint: Galderma Group
Compared with similar companies: very low dividend and very high price.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricevery high82
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 33.6 88 P/E (trailing 12 months) 66.0 81 Forward P/E 34.7 82 Price/book 6.59 81 Price/sales 7.54 80 Profitabilityaverage47
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 19.1% 45 ROE 10.8% 35 ROA 5.4% 37 Gross margin 69.4% 60 Net margin 14.6% 58 Earnings stabilitylow33
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.0% 57 Loss-making yearscounts in reverse: lower means more earnings stability 3 of 5 annual reports 9 Growthhigh78
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +11.08% 67 Revenue growth (year over year) +27.70% 78 Earnings growth (year over year) +130.70% 91 Financial strengthlow31
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.74 31 Interest coverage 5.12 22 Debt/equitycounts in reverse: lower means more financial strength 0.33 51 Current ratio 1.24 22 Dividendvery low12
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 2 years 9 Dividend yield 0.2% 11 Payout ratio 12.1% 15 Market momentumstrong70
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +2.72% 60 Relative strength (6 months) +5.72% 68 1-year return +27.35% 71 Distance from 200-day average +15.98% 82 Riskaverage49
How much the price swings.
Metric Value Position in group Volatility (60 days) 29.2% 58 Beta (1 year) 0.92 66 Maximum drawdown (12 months) 17.5% 23
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Galderma Group is pricier than similar companies
Galderma Group's P/E (trailing 12 months): 66.0, +164% against the median of a group of 11 similar companies (25.0).
Compared with 11 similar companies
| Metric | Galderma Group | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 66.0 | High | |
| Forward P/E | 34.7 | High | |
| Operating margin | 19.1% | Middle | |
| ROE | 10.8% | Middle | |
| Debt/equity | 0.33 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Galderma Group. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$3.15B
Latest quarter · Q2 2026
Net income
$444M
Latest quarter · Q2 2026
Quarterly net margin
14.1%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- CHF 44.63B
- P/E
- 66.0
- EPS
- CHF 2.90
- Volume
- 475.02K
- Daily trading
- €105.05M
- Dividend yield
- 0.18%
- Last ex-dividend on April 24, 2026
How Galderma Group is changing
All resultsRevenue grew 11.1% a year on average over the last 3 years
Operating margin rose from 10.5% to 16.9%
Profits turn into cash: free cash flow equal to 188% of net income
Returns
Galderma Group returns with dividends
CHF 1,000 invested in Galderma Group 1 year ago, on November 17, 2025, would be worth CHF 1,317 today with dividends reinvested: +31.70% in total, +31.70% per year. On price alone it would be CHF 1,314 (+31.42%).
| Period | Galderma Group | SMI | CHF 1,000 becomes |
|---|---|---|---|
| 1 month | +9.29% | +8.46% | CHF 1,093 |
| 6 months | +22.82% | +14.27% | CHF 1,228 |
| Year to date | +18.69% | +13.86% | CHF 1,187 |
| 1 year | +31.70% | +19.91% | CHF 1,317 |
Over the last 6 months it has done better than 36% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment
The chart in detail
Galderma Group: technical analysis
Galderma Group is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 1.4% below its all-time closing high (CHF 195.15, November 5, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 61
- Between 30 and 70
- vs 200-session average
- +16.43%
Support and resistance
Price areas where Galderma Group has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last priceCHF 192.40
- SupportCHF 183.97−4.38%2 touches, last on August 7, 2026
- SupportCHF 170.79−11.23%5 touches, last on September 30, 2026
- SupportCHF 167.02−13.19%6 touches, last on August 18, 2026
Volatility and risk
Over the last year it has moved roughly in line with the SMI.
- Beta (1 year) vs SMI
- 0.92
- Volatility (60 sessions, annualised)
- 29.1%
- Largest fall in the last year
- −17.49%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
Galderma Group and its competitors
Restylane, Dysport, Azzalure and Sculptra are among the injectable aesthetics brands people know best, while Cetaphil and ALASTIN cover dermatological skincare and Soolantra, Epiduo and Differin serve therapeutic dermatology. Galderma Group AG works across the dermatology market worldwide, offering aesthetic injectables, skincare products and treatments for skin conditions. Its portfolio also includes Oracea, AKLIEF, NEMLUVIO and Relfydess, and the company provides services alongside its brands. Its therapeutic range also includes Loceryl, Benzac and Metvix.
- Headquarters
- Zug, Switzerland
- Employees
- 7,676
- Founded
- 1981
- Chief executive
- Flemming Ornskov
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Galderma GroupGALD | $53.24B | 19.1% | 66.0 | +22.82% |
| Sandoz GroupSDZ | $43.66B | 9.3% | 72.3 | +30.60% |
| HaleonHLN | $40.03B | 23.5% | 19.2 | +4.51% |
| MerckMRK | $71.89B | 17.0% | 33.8 | +28.50% |
| Swedish Orphan BiovitrumSOBI | $16.42B | 30.9% | 25.0 | +8.39% |
| IpsenIPN | $15.16B | 27.4% | 26.9 | +0.60% |
Same industry or related industries, similar size. Compare Galderma Group with its competitors · Full profile
